Shapiro David 4
4 · INTERCEPT PHARMACEUTICALS, INC. · Filed Mar 1, 2019
Insider Transaction Report
Form 4
Shapiro David
Chief Medical Officer
Transactions
- Sale
Common Stock
2019-03-01$103.16/sh−2,000$206,320→ 40,543 total - Exercise/Conversion
Common Stock
2019-03-01$31.90/sh+2,000$63,800→ 42,543 total - Exercise/Conversion
Option to Purchase Common Stock
2019-03-01−2,000→ 13,031 totalExercise: $31.90Exp: 2023-05-07→ Common Stock (2,000 underlying)
Footnotes (2)
- [F1]This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]This option is fully vested and exercisable.